<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04483115</url>
  </required_header>
  <id_info>
    <org_study_id>TPN171H-P201</org_study_id>
    <nct_id>NCT04483115</nct_id>
  </id_info>
  <brief_title>Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension</brief_title>
  <official_title>Multi-center, Randomized，Placebo and Positive Controlled Clinical Study of TPN171H Tablets on Acute Haemodynamics in Patients With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vigonvita Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Institute of Materia Medica, Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vigonvita Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose&#xD;
      TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial&#xD;
      hypertension.The trial is expected to include 60 patients, divided into 6 groups, according&#xD;
      to 1:1:1:1:1:1 into the placebo group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil&#xD;
      tablets 20mg, 40mg group, each group 10 cases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-center, randomized, placebo and positive controlled phase IIa&#xD;
      proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute&#xD;
      hemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected&#xD;
      to include 60 patients, divided into 6 groups, according to 1:1:1:1:1:1 into the placebo&#xD;
      group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil tablets 20mg, 40mg group, each&#xD;
      group 10 cases. During the screening period, the tube placement period, and the observation&#xD;
      period, the patients will conduct various inspections and evaluation observations as&#xD;
      required.&#xD;
&#xD;
      The Swan-Ganz floating catheter and echocardiography were used to evaluate the efficacy of&#xD;
      TPN171H; PK parameters: including Tmax, Cmax, AUC0-t , t1/2,CL/F, Vz/F, λz; Safety evaluation&#xD;
      indicators include: vital signs, physical examination, laboratory examination (blood routine,&#xD;
      blood biochemistry, blood gas analysis), 12-lead ECG, adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of the maximum change in pulmonary vascular resistance(PVR) to the second baseline</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum change in PVR</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve for reduction in PVR</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in arterial oxygenation</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in right ventricular function</measure>
    <time_frame>Within 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>TPN171H 2.5mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPN171H 2.5mg tablet + Placebo 10mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPN171H 5mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPN171H 5mg tablet + Placebo 10mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPN171H 10mg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPN171H 10mg tablet + Placebo 5mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 5mg tablet+ Placebo 10mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tadalafil 20mg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tadalafil tablet 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tadalafil 40mg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tadalafil tablets 20mg *2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPN171H</intervention_name>
    <description>Tablets; Oral; Single dose</description>
    <arm_group_label>TPN171H 10mg group</arm_group_label>
    <arm_group_label>TPN171H 2.5mg group</arm_group_label>
    <arm_group_label>TPN171H 5mg group</arm_group_label>
    <other_name>Simmerafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets; Oral; Single dose</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tablets; Oral; Single dose</description>
    <arm_group_label>tadalafil 20mg group</arm_group_label>
    <arm_group_label>tadalafil 40mg group</arm_group_label>
    <other_name>ADCIRCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 to 75;&#xD;
&#xD;
          -  Patients who have voluntarily decided to participate in this study, and signed the&#xD;
             informed consent form;&#xD;
&#xD;
          -  Patients who are able to understand and follow study plans and instructions;&#xD;
&#xD;
          -  Patients with symtomatic PAH (Group1), a pulmonary vascular resistance (PVR) &gt; 3 Wood,&#xD;
             a mean pulmonary artery pressure (mPVP) ≥25 mmHg and a pulmonary artery wedge pressure&#xD;
             (PAWP) ≤ 15 mmHg either due to:&#xD;
&#xD;
               1. Idiopathic PAH (IPAH)&#xD;
&#xD;
               2. Familial PAH&#xD;
&#xD;
               3. Associated PAH due to drugs or toxins&#xD;
&#xD;
               4. Associated PAH due to connective tissue disease&#xD;
&#xD;
               5. Associated PAH due to congenital heart disease, if patients underwent surgical&#xD;
                  correction more than 1 year prior to screening&#xD;
&#xD;
          -  Have a current diagnosis of being in WHO functional class II or III;&#xD;
&#xD;
          -  Patients who are willing to take proper contraceptive during the study and within 3&#xD;
             months after the study completed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All types of PH except subtypes of Group1 specified in the inclusion criteria;&#xD;
&#xD;
          -  Moderate to severe COPD (FEV1 &lt; 60% predicted);&#xD;
&#xD;
          -  Moderate to severe restrictive lung disease (FVC &lt; 70% predicted);&#xD;
&#xD;
          -  Pre-treatment with PAH therapy within the last 1 months before the screening visit&#xD;
             (including endothelin receptor antagonists, PDE5 inhibitors, guanylate cyclase agonist&#xD;
             and prostacycline analogues);&#xD;
&#xD;
          -  A &quot;positive&quot; response to acute vasodilator testing;&#xD;
&#xD;
          -  Coagulation dysfunction (defined as activated partial thromboplastin time and&#xD;
             international normalized ratio are both &gt;1.5 times upper limit normal) or patients&#xD;
             with potential bleeding risk;&#xD;
&#xD;
          -  Hepatic dysfunction indicated by: serum bilirubin&gt;3 times upper limit normal, ALT and&#xD;
             AST&gt;2.5 times upper limit normal;&#xD;
&#xD;
          -  Renal insufficiency (creatinine clearance&lt;30 mL/min)；&#xD;
&#xD;
          -  Systolic blood pressure&lt;90 mmHg at screening;&#xD;
&#xD;
          -  QT prolongation at screening, whose values (QTcF) exceeding 450 msec in males and 470&#xD;
             msec in females;&#xD;
&#xD;
          -  Have enrolled in/or have a plan of an exercise training program for pulmonary&#xD;
             rehabilitation before the screening visit/or during the study;&#xD;
&#xD;
          -  Patients who have a recent (within 3 months) history of abusing alcohol or illicit&#xD;
             drugs;&#xD;
&#xD;
          -  Body weight&lt;40 kg；&#xD;
&#xD;
          -  Patients who have participated in a clinical study involving another investigational&#xD;
             drug within 1 month before the screening visit;&#xD;
&#xD;
          -  For any other reasons that affect compliance with the study protocol, especially the&#xD;
             long-term monitoring of floating catheters, according to the decision of&#xD;
             investigators;&#xD;
&#xD;
          -  HBV, HCV, HIV or Tp infection;&#xD;
&#xD;
          -  Patients with gastrointestinal, urinary, reproductive, immunologic, endocrine, or&#xD;
             central nervous system disease that, in the opinion of the investigator, will affect&#xD;
             the study;&#xD;
&#xD;
          -  Have a history of malignancies within 2 years, except for a cured basal cell or skin&#xD;
             squamous cell carcinoma;&#xD;
&#xD;
          -  Pregnant women, or breast feeding women;&#xD;
&#xD;
          -  Patients with hypersensitivity to iloprost or any of the excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yong Huo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huaqing Duan</last_name>
    <phone>+86-18061926005</phone>
    <email>huaqing.duan@vigonvita.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhicheng Jing</last_name>
      <email>jingzhicheng@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Huo</last_name>
      <email>huoyong@263.net.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuwai Hospital CAMS&amp;PUMC</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunshan Cao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daowen Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital Of Gannan Medical University</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiming Zhong</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lan Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>Acute Haemodynamic Study</keyword>
  <keyword>PK/PD study</keyword>
  <keyword>TPN171H</keyword>
  <keyword>Simmerafil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

